Previous 10 |
DENVER, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Nexien BioPharma, Inc. ("Nexien"or the"Company") (OTCQB:NXEN), a next generation biopharmaceutical company focused on research, development and commercialization of novel FDA-compliant cannabinoid pharmaceuticals and related drug delivery systems, t...
The patent relates to the administration of a specific composition comprised of cannabinoids to a patient Nexien BioPharma, Inc. (“Nexien” or the “Company”) (OTCQB: NXEN), a next generation biopharmaceutical company focused on research, development and comme...
Nexien BioPharma, Inc. (“Nexien” or the “Company”) (OTCQB: NXEN), a next generation biopharmaceutical company focused on research, development and commercialization of novel FDA-compliant cannabinoid pharmaceuticals and related drug delivery systems, today announce...
DENVER, CO / ACCESSWIRE / March 28, 2019 / Nexien BioPharma, Inc. ("Nexien" or the "Company") (OTCQB: NXEN), a next generation biopharmaceutical company focused on research, development, and commercialization of advanced FDA Compliant cannabinoid pharmaceuticals and related drug delivery sys...
-- Patent covers use of cannabinoids and terpenes for treatment of organophosphate and carbamate toxicity -- Nexien BioPharma, Inc. (“Nexien” or the “Company”) (OTCQB: NXEN), a next generation biopharmaceutical company focused on research, development and com...
-- Encouraging clinical observations and patient questionnaire results indicate that specific cannabinoid formulations are supportive in the treatment of patients suffering from myotonic dystrophy -- Nexien BioPharma, Inc. (“Nexien” or the “Company”) (OTCQB: ...
Nexien BioPharma, Inc. (“Nexien” or the “Company”) (OTCQB:NXEN), a next generation biopharmaceutical company focused on research, development and commercialization of novel FDA-compliant cannabinoid pharmaceuticals and related drug delivery systems, today announce...
News, Short Squeeze, Breakout and More Instantly...
Bank of Georgia Group Plc (BDGSF) is expected to report for Q1 2024 iCad Inc. (ICAD) is expected to report for Q1 2024 Yasheng Group (HERB) is expected to report for Q1 2024 Bit Digital Inc. (BTBT) is expected to report $0.01 for Q1 2024 Estrella Immunopharma Inc. (ESLA) is expect...
Owens Corning Inc New (OC) is expected to report $2.82 for Q4 2023 Getty Realty Corporation (GTY) is expected to report $0.56 for Q4 2023 Bion Environmental Technologies Inc. (BNET) is expected to report for Q2 2024 Nexien BioPharma Inc (NXEN) is expected to report for Q2 2024 Ayt...
The RMR Group Inc. (RMR) is expected to report $0.46 for Q4 2023 Indra Sistemas ADR (ISMAY) is expected to report for Q3 2023 Ceapro Inc. (CRPOF) is expected to report for Q2 2024 Tuya Inc. American Depositary Shares each representing one Class A (TUYA) is expected to report $-0.02 fo...